Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready?

Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We... Ann Surg Oncol (2018) 25:1803–1806 https://doi.org/10.1245/s10434-018-6516-4 EDITORIAL – MELANOMAS Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready? Charles M. Balch, MD, FACS, FASCO University of Texas MD Anderson Cancer Center, Houston, TX In the past decade, powerful new immunotherapy agents vaccines have failed in the past decades. Thus, in a ‘‘tol- have demonstrated remarkable improvements in survival of erant state,’’ most cancer patients cannot respond to patients with many histological types of stage IV cancer, as treatment approaches that involve increased antigen pre- first demonstrated in metastatic melanoma and reported in sentation (e.g., vaccines) or immune stimulants (e.g., 2010. With a new understanding of the immune system interferons or interleukins). With the availability of and a growing portfolio of powerful immunotherapy checkpoint inhibitors to ‘‘break tolerance,’’ the immune agents, survival rates in stage IV melanoma patients have system can now recognize and destroy metastases as it dramatically increased from a historical median survival of would any ‘‘foreign invader,’’ such as viruses or trans- 2–9 months, to a remarkable median survival exceeding planted tissues. With multiple checkpoint inhibitors 24 months, with approximately 20% of patients remaining approved for cancer, an entirely new landscape http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready?

Loading next page...
 
/lp/springer_journal/revolutionary-advances-in-immunotherapy-for-melanoma-are-coming-into-Z1Ae9Yd07H
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery
ISSN
1068-9265
eISSN
1534-4681
D.O.I.
10.1245/s10434-018-6516-4
Publisher site
See Article on Publisher Site

Abstract

Ann Surg Oncol (2018) 25:1803–1806 https://doi.org/10.1245/s10434-018-6516-4 EDITORIAL – MELANOMAS Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready? Charles M. Balch, MD, FACS, FASCO University of Texas MD Anderson Cancer Center, Houston, TX In the past decade, powerful new immunotherapy agents vaccines have failed in the past decades. Thus, in a ‘‘tol- have demonstrated remarkable improvements in survival of erant state,’’ most cancer patients cannot respond to patients with many histological types of stage IV cancer, as treatment approaches that involve increased antigen pre- first demonstrated in metastatic melanoma and reported in sentation (e.g., vaccines) or immune stimulants (e.g., 2010. With a new understanding of the immune system interferons or interleukins). With the availability of and a growing portfolio of powerful immunotherapy checkpoint inhibitors to ‘‘break tolerance,’’ the immune agents, survival rates in stage IV melanoma patients have system can now recognize and destroy metastases as it dramatically increased from a historical median survival of would any ‘‘foreign invader,’’ such as viruses or trans- 2–9 months, to a remarkable median survival exceeding planted tissues. With multiple checkpoint inhibitors 24 months, with approximately 20% of patients remaining approved for cancer, an entirely new landscape

Journal

Annals of Surgical OncologySpringer Journals

Published: May 11, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off